Adma Biologics (ADMA) Short-term Investments (2014 - 2017)

Adma Biologics (ADMA) has 4 years of Short-term Investments data on file, last reported at $1.5 million in Q4 2017.

• Quarterly Short-term Investments fell 72.17% year-over-year to $1.5 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $1.5 million (down 72.17% YoY) and the FY2017 annual result came in at $1.5 million, down 72.17% from the prior year.
• Short-term Investments rose to $1.5 million in Q4 2017, from $245000.0 in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $6.4 million in Q4 2015 to a low of $245000.0 in Q1 2017.
• A 4-year average of $3.6 million and a median of $4.7 million in 2014 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2015 — Short-term Investments soared 36.87% — and 2017, when it sank 72.17%.
• Tracing ADMA's Short-term Investments over 4 years: stood at $4.7 million in 2014, then surged by 36.87% to $6.4 million in 2015, then dropped by 15.36% to $5.4 million in 2016, then slumped by 72.17% to $1.5 million in 2017.
• The last three Short-term Investments figures came in at $1.5 million (Q4 2017), $245000.0 (Q1 2017), and $5.4 million (Q4 2016), per Business Quant data.